Literature DB >> 15164997

Eye muscle antibodies in Graves' ophthalmopathy: pathogenic or secondary epiphenomenon?

T Mizokami1, M Salvi, J R Wall.   

Abstract

The extra ocular (eye) muscles are one of the principal tissues involved in the autoimmune-mediated inflammation of Graves' ophthalmopathy (GO). Several eye muscle proteins are targeted by autoantibodies or sensitized T lymphocytes, or both, and include: G2s, which is now identified as the terminal 141 amino acids of the winged-helix transcription factor FOXP1, the flavoprotein (Fp) subunit of the mitochondrial enzyme succinate dehydrogenase, the so-called "64kDa protein", a non-tissue specific membrane protein called 1D and the calcium binding protein calsequestrin. Of these, antibodies against G2s and Fp are the most sensitive markers of eye muscle damage in patients with thyroid autoimmunity even though neither antigen is specific to eye muscle and neither antibody is specific to GO. However, the recent finding that the calsequestrin gene is 4.7 times more expressed in eye muscles than other skeletal muscles suggests that we should reconsider the possible role of anti-calsequestrin autoantibodies in ophthalmopathy. GO may comprise two main subtypes with different pathogenetic mechanisms, namely ocular myopathy in which eye muscle inflammation predominates and congestive ophthalmopathy where inflammatory changes occur in the periorbital connective tissues in the absence of eye muscle dysfunction. Anti-G2s and anti-Fp antibodies are closely associated with the ocular myopathy subtype of GO while antibodies targeting type XIII collagen, the only member of the collagen family to have a transmembrane domain, are closely linked to congestive ophthalmopathy. Since both G2s and Fp are intracellular antigens it is unlikely that either antibody causes eye muscle fiber damage in GO, although a role in the later stages of the disease when the fiber has released its cellular contents has not been excluded. Eye muscle antibodies that are cytotoxic to eye muscle cells in antibody-dependent cell-mediated cytotoxicity (ADCC) are more likely to play a role in eye muscle fiber damage since they target a putative eye muscle cell membrane antigen, the identity of which is currently being investigated. While anti-G2s and anti-Fp antibodies are probably secondary to an underlying reaction, such as cytotoxic T lymphocyte targeting of an eye muscle membrane antigen that has yet to be identified, they are reliable markers of immunologically mediated eye muscle fiber damage in patients with Graves' hyperthyroidism. In conclusion, while a pathogenic role for eye muscle antibodies has not been excluded, they are most likely secondary to cytotoxic T cell reactions in GO and, as such, good markers of this autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15164997     DOI: 10.1007/BF03345270

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  62 in total

1.  Serum antibodies against the flavoprotein subunit of succinate dehydrogenase are sensitive markers of eye muscle autoimmunity in patients with Graves' hyperthyroidism.

Authors:  K Gunji; A De Bellis; S Kubota; J Swanson; S Wengrowicz; B Cochran; B A Ackrell; M Salvi; A Bellastella; A Bizzarro; A A Sinisi; J R Wall
Journal:  J Clin Endocrinol Metab       Date:  1999-04       Impact factor: 5.958

Review 2.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

Review 3.  Graves' disease is a multi-system autoimmune disorder in which extra ocular muscle damage and connective tissue inflammation are variable features.

Authors:  Jack R Wall
Journal:  Thyroid       Date:  2002-01       Impact factor: 6.568

4.  Immunohistochemical evidence for IgE involvement in Graves' orbitopathy.

Authors:  R B Raikow; M H Dalbow; J S Kennerdell; K Compher; L Machen; W Hiller; D Blendermann
Journal:  Ophthalmology       Date:  1990-05       Impact factor: 12.079

Review 5.  Nature and significance of eye muscle autoantigens in endocrine ophthalmopathy.

Authors:  J R Wall
Journal:  Dev Ophthalmol       Date:  1993

6.  Prevalence and significance of antibodies reactive with eye muscle membrane antigens in sera from patients with Graves' ophthalmopathy and other thyroid and nonthyroid diseases.

Authors:  Y J Wu; E M Clarke; P Shepherd
Journal:  Thyroid       Date:  1998-02       Impact factor: 6.568

7.  Cloning and sequencing of a novel 64-kDa autoantigen recognized by patients with autoimmune thyroid disease.

Authors:  Q Dong; M Ludgate; G Vassart
Journal:  J Clin Endocrinol Metab       Date:  1991-06       Impact factor: 5.958

8.  Type XIII collagen is identified as a plasma membrane protein.

Authors:  P Hägg; M Rehn; P Huhtala; T Väisänen; M Tamminen; T Pihlajaniemi
Journal:  J Biol Chem       Date:  1998-06-19       Impact factor: 5.157

9.  Experimental model for ophthalmopathy in BALB/c and outbred (CD-1) mice genetically immunized with G2s and the thyrotropin receptor.

Authors:  Masayo Yamada; Audrey Wu Li; Kenneth A West; Cheng-Hsien Chang; Jack R Wall
Journal:  Autoimmunity       Date:  2002-09       Impact factor: 2.815

10.  Prevalence of antibodies reactive with a 64 kDa eye muscle membrane antigen in thyroid-associated ophthalmopathy.

Authors:  M Salvi; N Bernard; A Miller; Z G Zhang; E Gardini; J R Wall
Journal:  Thyroid       Date:  1991       Impact factor: 6.568

View more
  14 in total

1.  Time course of Graves' ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study.

Authors:  Annamaria De Bellis; Giovanni Conzo; Gilda Cennamo; Elena Pane; Giuseppe Bellastella; Caterina Colella; Assunta Dello Iacovo; Vanda Amoresano Paglionico; Antonio Agostino Sinisi; Jack R Wall; Antonio Bizzarro; Antonio Bellastella
Journal:  Endocrine       Date:  2011-11-16       Impact factor: 3.633

2.  Graves' ophthalmopathy: search for shared autoantigen(s) continues.

Authors:  L Bartalena
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

3.  Antibodies targeting the calcium binding skeletal muscle protein calsequestrin are specific markers of ophthalmopathy and sensitive indicators of ocular myopathy in patients with Graves' disease.

Authors:  B Gopinath; R Musselman; N Beard; S El-Kaissi; J Tani; C-L Adams; J R Wall
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

4.  Rituximab treatment in patients with active Graves' orbitopathy: effects on proinflammatory and humoral immune reactions.

Authors:  G Vannucchi; I Campi; M Bonomi; D Covelli; D Dazzi; N Currò; S Simonetta; P Bonara; L Persani; C Guastella; J Wall; P Beck-Peccoz; M Salvi
Journal:  Clin Exp Immunol       Date:  2010-09       Impact factor: 4.330

Review 5.  Immunopathogenesis of thyroid eye disease: emerging paradigms.

Authors:  Vibhavari M Naik; Milind N Naik; Robert A Goldberg; Terry J Smith; Raymond S Douglas
Journal:  Surv Ophthalmol       Date:  2010 May-Jun       Impact factor: 6.048

6.  Increased expression of TSH receptor by fibrocytes in thyroid-associated ophthalmopathy leads to chemokine production.

Authors:  Erin F Gillespie; Konstantinos I Papageorgiou; Roshini Fernando; Nupur Raychaudhuri; Kimberly P Cockerham; Laya K Charara; Allan C P Goncalves; Shuang-Xia Zhao; Anna Ginter; Ying Lu; Terry J Smith; Raymond S Douglas
Journal:  J Clin Endocrinol Metab       Date:  2012-03-07       Impact factor: 5.958

7.  Immunohistochemical studies using immunized Guinea pig sera with features of anti-human thyroid, eye and skeletal antibody and Graves' sera.

Authors:  Ildikó Molnár; Zita Szombathy; Ilona Kovács; A József Szentmiklósi
Journal:  J Clin Immunol       Date:  2007-01-23       Impact factor: 8.317

8.  A mutant collagen XIII alters intestinal expression of immune response genes and predisposes transgenic mice to develop B-cell lymphomas.

Authors:  Anne Tuomisto; Malin Sund; Jenni Tahkola; Anne Latvanlehto; Eeva-Riitta Savolainen; Helena Autio-Harmainen; Annikki Liakka; Raija Sormunen; Jussi Vuoristo; Anne West; Riitta Lahesmaa; Herbert C Morse; Taina Pihlajaniemi
Journal:  Cancer Res       Date:  2008-12-15       Impact factor: 12.701

9.  Rituximab induces distinct intraorbital and intrathyroidal effects in one patient satisfactorily treated for Graves' ophthalmopathy.

Authors:  P Bonara; G Vannucchi; I Campi; S Rossi; F Cantoni; C Frugoni; F Sbrozzi; C Guastella; S Avignone; P Beck-Peccoz; M Salvi
Journal:  Clin Rev Allergy Immunol       Date:  2008-02       Impact factor: 8.667

Review 10.  Pathogenesis of Graves' ophthalmopathy: the role of autoantibodies.

Authors:  Teck Kim Khoo; Rebecca S Bahn
Journal:  Thyroid       Date:  2007-10       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.